Please assess the completion status of the following clinical trial:

Trial Title: Effect of Locally Administered Morphine and Bupivicaine on Acute and Chronic Postmastectomy Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* female patients with cancer breast scheduled for modified radical mastectomy with axillary dissection~Exclusion Criteria:~* allergy to the study drugs~* significant cardiac, respiratory, renal or hepatic disease~* drug or alcohol abuse~* psychiatric illness that would interfere with perception and assessment of pain

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- local instillation of morphine 5 mg (Type: ACTIVE_COMPARATOR): 5 ml plain bupivacaine 0.5% and 5 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
- local instillation of morphine 10 mg (Type: ACTIVE_COMPARATOR): 5 ml plain bupivacaine 0.5% and 10 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
- local instillation of morphine 15 mg (Type: ACTIVE_COMPARATOR): 5 ml plain bupivacaine 0.5% and 15 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
- local instillation of local anesthetics (Type: PLACEBO_COMPARATOR): 5 ml plain bupivacaine 0.5% .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).